White House looks for path to provide experimental Ebola drugs to infected patients

Drugmakers who sell unapproved drugs are generally setting themselves up for big penalties from federal authorities. The Obama administration, under mounting pressure, intends to craft a policy for using experimental drugs to treat the Ebola virus, Reuters reports. The White House Friday said it is setting up a working group to consider the use of drugs on the hundreds patients in Africa infected by the deadly virus, which has killed nearly 1,000 so far. The FDA already allowed an experimental drug from California-based Mapp Biopharmaceutical to be used to treat two U.S. aid workers who became infected. But any accelerated use of the drugs poses potential threats to patients and the drugmakers, so a policy and pathway to use will have to be designed carefully. Story | More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.